Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2005-06-14
2005-06-14
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C536S028500, C536S028510, C536S028520, C549S511000, C546S113000, C514S009100, C514S011400, C514S449000, C514S459000, C514S460000
Reexamination Certificate
active
06905669
ABSTRACT:
Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
REFERENCES:
patent: 5283383 (1994-02-01), Boyd et al.
patent: 6110697 (2000-08-01), Dulski et al.
patent: 2002/0114809 (2002-08-01), Rubinfeld et al.
patent: WO 98/55449 (1998-12-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/069903 (2002-09-01), None
Zhu et al., DNA Methyltransferase Inhibition Enhances Apoptosis Induced by Histone Deacetylase Inhibitors. Cancer Research 61, 1327-1333 (Feb. 15, 2001).
Saito et al., A Synthetic inhibitor of Histone Deacetylase, MS-27-275, with Marked in vivo Antitumor activity against Human Tumors. Proc. Natl.Acad. Sci. USA 96, 4592-4597 (Apr. 1999).
Zhu et al., A nonsteriodal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCap cells. Endocrinology 140, 5451-5454 (Nov. 1999).
Yoshida et al., J. Biol. Chem. 265, 17174-17179 (1990).
Guan et al. Drg-1 as differentiation-related putative metastatic suppressor gene in human colon cancer. Cancer Research 60, 749-755 (Feb. 2000).
Nakayama et al., Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Invest. 80, 1789-1796 (Dec. 2000).
Kijima et al., Trtapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268, 22429-22435 (1993).
Cameron et al. Synergy of demethylation and histone deacetlase inhibition in the re-expression of genes silenced in cancer. Nature Genetics 21, 103-107 (Jan. 1999).
Sheikhnejad, G. et al., “Mechanism of inhibition of DNA (cytosine C5)- methyltransferases by oligodeoxyribonucleotides containing 5, 6-dihydro-5-azacytosine”,J. Mol. Biol.,1999, pp. 2021-2034, vol. 285.
Goffin, J. et al., “DNA methyltransferase inhibitors—state of the art”,Annals of Oncology,2002, pp. 1699-1716, vol. 13.
Wijermans, P. et al., “Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients”,Journal of Clinical Oncology,Mar. 2000, pp. 956-962, vol. 18, No. 5.
Goffin, J., et al., “DNA Methyltransferase Inihibitors-State of the Art, ”Annals of Oncology(2002) vol. 13, pp. 1699-1716.
Sheikhnejad, G., et al., “Mechanism of Inhibition of DNA (Cytosine C5)- Methyltransferases by Oligodeoxyribonucleotides Containing 5, 6-Dihydro-5- Azacytosine,”J. Mol. Biol.(1999) vol. 285, pp. 2021-2034.
Wijermans, P., et al., “Low-Dose 5-Aza-2′ -Deoxycytidine, a DNA Hypomethylating Agent, for The Treatment of High-Risk Mylodyplastic Snydrome: A Multicenter Phase II Study in Elderly Patients,”Journal of Clinical Oncology(2000) vol. 18, No. 5, pp. 956-962.
Baylin, S.B., et al., “Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia,”Cancer Res.,(1998) 72:141-196.
Daskalakis,M., et al., “Expression of a Hypermethylated and Silenced P15/INK4B Gene in a Subgroup of MDS Patients is Restored by Treatment With The Methylation Inhibitor 5-AZA-2'-Deoxycytidine,”Abstracts Leukemia Research(2001) Suppl. No. 1, S16-S17.
Esteller, M., “A Gene Hypermethylation Profile of Human Cancer,”Cancer Research(2001) 61:3225-3229.
Esteller, M., “CpG Island Hypermethylation and Tumor Suppressor Genes: a Booming Present, a Brighter Future,”Oncogene(2002) 21:5427-5440.
Esteller, M., “Epigenetic Lesions Causing Genetic Lesions in Human Cancer: Promoter Hypermethylation of DNA Repair Genes,”European Journal of Cancer(2000) 36:2294-2300.
Gagnon, J., et al., “Interaction of 5-aza-2'-deoxycytidine and Depsipeptide on Antineoplastic Activity and Activation of 14-3-3σ, E-Cadherin And Tissue Inhibitor of Metalloproteinase 3 Expression in Human Breast Carcinoma Cells,”Anti-Cancer Drugs,(2003), 14(3):193-202.
Jones, P.A., “DNA Methylation And Cancer,”Oncogene,(2002) 21:5358-5360.
Jones, P.A., et al., “The Fundamental Role of Epigenetic Events in Cancer,”Nature Reviews/Genetics,(2002) 3:415-428.
Jones, P.A., et al., “The Role of DNA Methylation in Cancer,”Adv. Cancer Res.,(1990) 54:1-23.
Karpf, A.R., et al., “Reactivating The Expression of Methylation Silenced Genes in Human Cancer,”Oncogene,(2002) 21:5496-5503.
La Rosee, P., et al., “In Vitro Efficacy of Combined Treatment Depends on the Underlying Mechanism of Resistance in Imatinib-Resistant Bcr-Abl positive Cell Lines,”Blood First Edition Paper,prepublished online (2003) DOI 10.1182/blood-2003-04-1074, pp. 1-39.
Nephew, K.P., et al., “Epigenetic Gene Silencing in Cancer Initiation And Progression,”Cancer Letters 190,(2003) pp. 125-133.
Paz, M.F., et al., “A Systematic Profile of DNA Methylation in Human Cancer Cell Lines,”Cancer Research 63,(2003) 1114-1121.
Primeau, M., et al., “Synergistic Antineoplastic Action of DNA Methylation Inhibitor 5- AZA-2'-Deoxycytidine and Histone Deacetylase Inhibitor Depsipeptide on Human Breast Carcinoma Cells,”Int. J. Cancer,(2003) 103:177-184.
Santini, V., et al., “Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications,”Annals of Internal Medicine(2001) 134:573-586.
Schrump, D.S., et al., “Phase 1 Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients With Malignancies Involving Lungs or Pleura,”Clinical Lung Cancer,(2002) 186-192.
Shaker, S., et al., “Preclinical Evaluation of Antineoplastic Activity of Inhibitors of DNA Methylation (5-aza-2'-deoxycytidine) and Histone Deacetylation (Trichostatin A, Depsipeptide) in Combination Against Myeloid Leukemic Cells,”Leukemia Research 27,(2003) 437-444.
Smiraglia, D.J., et al., “The Study of Aberrant Methylation in CancerviaRestriction Landmark Genomic Scanning,”Oncogene,(2002) 21:5414-5426.
Wajed, S.A., et al., “DNA Methylation: An Alternative Pathway to Cancer,”Annals of Surgery(2001), 234(1):10-20.
Weiser, T.S., “Sequential 5-Aza-2'-Deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells And Facilities Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1,”Journal of Immunotherapy,(2001), 24(2):151-161.
Minoru Yoshida et al., “Potent and Specific Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A” J. Biol. Chem Oct. 15, 1990, vol. 265, No. 28, pp. 17174-17179.
Villanueva et al., “Induction of HTLV-1 Tax and Immune Genes in Infected Cells by Histone Deacetylase Inhibition and DNA Demethylation Agents”, FASEB Journal, Mar. 2001, vol 15, No. 5, p. A1230, See Abstract B-631A.
Lan Yan et al., “Role of DNA Methylation and Histone Acetylation in Steriod Receptor Expression in Breast Cancer1,4,” J. Mammary Gland Biology and Neoplasia, Apr. 2001, vol. 6, No. 2, pp. 183-192. See p. 189.
Coffee, et al., “Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells”, Nature Genetics, vol. 22, pp. 98-101 (1999).
Endres, et al., “DNA Methyltransferase Contributes to Delayed Ischemic Brain Injury”, The Journal of Neuroscience, 20(9):3175-3181 (2000).
Koshy, et al., “2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia”, Clinical Observations, Interventions, and Therapeutic Trials, Blood, vol. 96, No. 7, pp. 2379-2384 (2000).
Marks, et al., “Histone Deace
Kam Chih-Min
SuperGen, Inc.
Weber Jon
LandOfFree
Compositions and methods for reestablishing gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for reestablishing gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for reestablishing gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3482157